Vir Biotechnology, Inc. Common Stock
VIR Real Time Price USDRecent trades of VIR by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by VIR's directors and management
Government lobbying spending instances
-
$50,000 Oct 18, 2024 Issue: Budget/Appropriations Government Issues Health Issues
-
$50,000 Jul 14, 2024 Issue: Budget/Appropriations Government Issues Health Issues
-
$50,000 Apr 14, 2024 Issue: Budget/Appropriations Government Issues Health Issues
-
$70,000 Nov 03, 2023 Issue: Trade (domestic/foreign) Taxation/Internal Revenue Code Medicare/Medicaid Science/Technology Health Issues
-
$140,000 Oct 20, 2023 Issue: Trade (domestic/foreign) Taxation/Internal Revenue Code Medicare/Medicaid Science/Technology Health Issues
-
$160,000 Jul 20, 2023 Issue: Trade (domestic/foreign) Taxation/Internal Revenue Code Medicare/Medicaid Science/Technology Health Issues
-
$150,000 Oct 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Science/Technology Health Issues
-
$140,000 Jul 20, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid Science/Technology Health Issues
-
$170,000 Apr 20, 2022 Issue: Medicare/Medicaid Science/Technology Health Issues
-
$120,000 Jan 20, 2022 Issue: None
-
$170,000 Oct 20, 2021 Issue: None
-
$30,000 Jul 19, 2021 Issue: Health Issues
-
$90,000 Jul 18, 2021 Issue: Health Issues Government Issues
-
$30,000 Apr 20, 2021 Issue: Health Issues
-
$90,000 Apr 20, 2021 Issue: Health Issues Government Issues
-
$90,000 Jan 20, 2021 Issue: Budget/Appropriations Government Issues Health Issues
-
$30,000 Jan 19, 2021 Issue: Health Issues
-
$90,000 Oct 20, 2020 Issue: Health Issues Budget/Appropriations Government Issues
-
$90,000 Jul 19, 2020 Issue: Government Issues Health Issues
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Hiv vaccines comprising one or more population episensus antigens Apr. 18, 2023
-
Patent Title: Hiv vaccines comprising one or more population episensus antigens Jan. 17, 2023
-
Patent Title: Antibodies against sars-cov-2 and methods of using the same Oct. 25, 2022
-
Patent Title: Antibodies against sars-cov-2 and methods of using the same Nov. 09, 2021
-
Patent Title: Hiv vaccines comprising one or more population episensus antigens Jan. 19, 2021
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of VIR in WallStreetBets Daily Discussion
Recent insights relating to VIR
Recent picks made for VIR stock on CNBC
ETFs with the largest estimated holdings in VIR
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view VIR Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.